Show simple item record

dc.contributor.authorNath, Karthik
dc.contributor.authorReyaldeen, Reza
dc.contributor.authorPalamuthusingam, Dharmenaan
dc.date.accessioned2019-12-06T02:22:34Z
dc.date.available2019-12-06T02:22:34Z
dc.date.issued2019
dc.identifier.issn1444-0903
dc.identifier.doi10.1111/imj.14452
dc.identifier.urihttp://hdl.handle.net/10072/389575
dc.description.abstractWe congratulate Leitinger et al.1 and co‐authors for their comprehensive review on the use of proton‐pump inhibitors (PPI) in patients with malignant haematological conditions. The authors highlight the high prophylactic and often extended use of PPI in patients receiving treatment for multiple myeloma, lymphoma and recipients of autologous haemopoietic stem cell transplantation. In those with multiple myeloma or lymphoma there was no strong indication for the initiation of PPI in more than half the patients studied. Furthermore, therapy was typically continued for a protracted duration, sometimes indefinitely despite no indication for therapy. Studies involving the general population from the United States and the United Kingdom have also reported up to 70% of PPI prescription without indication.2, 3 The authors have also highlighted the paucity of robust evidence on the indications for prophylaxis in those patients receiving glucocorticoid therapy. Their national survey demonstrated high variability in clinical practice and an overall lack of institutional protocols for the use of PPI therapy in this setting.
dc.languageEnglish
dc.language.isoeng
dc.publisherWiley
dc.publisher.placeAustralia
dc.relation.ispartofpagefrom1337
dc.relation.ispartofpageto1337
dc.relation.ispartofissue10
dc.relation.ispartofjournalInternal Medicine Journal
dc.relation.ispartofvolume49
dc.subject.fieldofresearchClinical Sciences
dc.subject.fieldofresearchCardiorespiratory Medicine and Haematology
dc.subject.fieldofresearchPublic Health and Health Services
dc.subject.fieldofresearchcode1103
dc.subject.fieldofresearchcode1102
dc.subject.fieldofresearchcode1117
dc.subject.keywordsLife Sciences & Biomedicine
dc.subject.keywordsGeneral & Internal Medicine
dc.subject.keywordsScience & Technology
dc.titleProton-pump inhibitor overuse: a cautionary tale in misguided benefit (Letter)
dc.typeJournal article
dc.type.descriptionC2 - Articles (Other)
dcterms.bibliographicCitationNath, K; Reyaldeen, R; Palamuthusingam, D, Proton-pump inhibitor overuse: a cautionary tale in misguided benefit, Internal Medicine Journal, 2019, 49 (10), pp. 1337-1337
dcterms.dateAccepted2019-07-08
dc.date.updated2019-12-02T00:26:58Z
dc.description.versionAccepted Manuscript (AM)
gro.rights.copyright© 2019 Royal Australasian College of Physicians. This is the peer reviewed version of the following article: Proton-pump inhibitor overuse: a cautionary tale in misguided benefit, Internal Medicine Journal, Vol. 49, Iss. 10, October 2019, Pages 1337-1337, which has been published in final form at 10.1111/imj.14452. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving (http://olabout.wiley.com/WileyCDA/Section/id-828039.html)
gro.hasfulltextFull Text
gro.griffith.authorPalamuthusingam, Dharmenaan


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record